Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Table 2

Adverse events.

	Number of patients (%); Ibrutinib plus obinutuzumab (n = 32)
	Any grade	Grade 3-4
All	32 (100)	25 (78)
Nonhematological
Hyperglycemia	23 (72)	2 (6)
AST increased	16 (50)	1 (3)
Diarrhea	14 (44)	1 (3)
Infections (skin, lung, and eye)	7 (22)	1 (3)
Hyponatremia	7 (22)	1 (3)
Hypocalcemia	7 (22)	1 (3)
Blood bilirubin increased	11 (34)	0 (0)
Fever	11 (34)	0 (0)
Fatigue	11 (34)	0 (0)
Hyperphosphatemia	10 (31)	0 (0)
ALT increased	10 (31)	0 (0)
Hyperkalemia	8 (25)	0 (0)
Creatinine increased	6 (19)	0 (0)
Headache	6 (19)	0 (0)
Flu-like symptoms	6 (19)	0 (0)
Arthralgia	5 (16)	0 (0)
Alkaline phosphatase increased	4 (12)	0 (0)
Back pain	4 (12)	0 (0)
Neck pain	3 (9)	0 (0)
Atrial fibrillation	2 (6)	0 (0)
Hematological
Neutropenia	18 (56)	11 (34)
Thrombocytopenia	25 (75)	8 (25)
Anemia	8 (25)	0 (0)